KR20120048882A - Composition comprising acanthopanacis cortex butanol fraction for preventing or treating gastrointestinal disease - Google Patents

Abstract

PURPOSE: A composition containing a butanol fraction of Acanthopanacis cortex is provided to suppress growth of helicobacter pylori and to ensure excellent antibacterial activity. CONSTITUTION: A composition for preventing or treating gastrointestinal diseases, gastritis, gastric ulcer, duodenal ulceration contains a butanol fraction of Acanthopanacis cortex as an active ingredient. The butanol fraction is prepared by extracting alcohol crud extract of Acanthopanacis cortex using n-hexane, ethyl acetate, and n-butanol in order. The extract is prepared using leaves, ligneous parts(stems and branches), roots, fruits, or flowers. The composition is a pharmaceutical or food composition.

Description

Composition comprising Acanthopanacis Cortex butanol fraction for preventing or treating gastrointestinal disease}

The present invention relates to a composition for the prevention or treatment of gastrointestinal diseases, containing the Ogapi butanol fraction as an active ingredient.

The stomach is a long-term organ that stores food from the esophagus and breaks it down easily for digestion, and regulates the sending of food to the duodenum in harmony with the secretion of pancreatic enzymes for efficient digestion and absorption. The stomach secretes gastric acid, a strong acid, to digest food when it comes in. The protective layer of the gastric mucosa acts to prevent damage to the gastric mucosa by gastric acid. The gastric mucosal protective layer that protects the stomach is susceptible to damage from various types of factors. Representative attack factors include bacteria such as nonsteroidal anti-inflammatory drugs (NSAID) such as gastric acid, alcohol, aspirin, and helicobacter pylori, microcirculation disorders of hypoxia induced by stress and hypotension. Due to these factors, when the gastric mucosal layer is damaged, inflammation occurs with erosion, redness, bleeding, and swelling. When the gastric mucosa is damaged and penetrates the gastric mucosa and is damaged to the lower mucosa and the muscle layer, gastric ulcer occurs. In addition, due to the above factors, duodenal mucosa is damaged and dug deeper than the mucosal layer on the surface, and damage to the mucosal myocardium occurs.

Therefore, in order to treat gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer caused by the above-mentioned attack factors, inhibition of gastric acid secretion, inhibition of proliferation of Helicobacter pylori bacteria, promotion of mucous secretion, promotion of epithelial cell regeneration, anti-inflammatory, etc. Drugs with efficacy are needed.

At present, the most representative treatments for gastrointestinal diseases include antacids that neutralize excessive gastric secretions, histamine H ₂ receptor antagonists and proton pump inhibitors that inhibit gastric acid secretion, increase gastric lining resistance to digestive fluids, and increase acid resistance. Prostaglandin or gastric mucosa protective agent that can inhibit secretion.

Antacids in the drug are intended for temporary fastness, not for fundamental treatment, and exhibit medicinal effects by lowering the activity of pepsin by raising the pH in the stomach. However, side effects such as constipation, diarrhea, metabolic alkalosis, urolithiasis, and the like have been reported by the administration of an inorganic substance when antacids are used, and recently, acid rebound due to antacids has been a problem.

In addition, cimetidine, the most widely used histamine H ₂ receptor antagonist, blocks histamine receptors in the gastric mucosa and blocks histamine molecules so that histamine molecules do not signal acid secretion. It does not work. Full-scale treatment of gastric ulcers began with the release of cimetidine in 1977, and several derivatives have been developed. Among them, ranitidine, famotidine, roxatidine, and nizatidine have excellent anti-ulcer effects in clinical practice due to shortening of treatment period, but relapse rate after stopping drug administration There is a high disadvantage. In addition, cimetidine exhibits side effects such as decreased libido in men, gynecomastia in men, and neutropenia, and drug interactions, and thus the use of cimetidine has been avoided. Is witnessing a significant decrease.

In addition, proton pump inhibitors include omeprazole and lansoprazol, which are known to exhibit potent acid secretion effects by inhibiting acid secretion in gastric wall cells at a final stage. However, the relapse rate has not been reduced even in ulcer healing patients with these drugs, and side effects such as stool, diarrhea, fever, headache and fatigue have been reported.

As described above, the development of antisecretory agents such as histamine H ₂ receptor antagonists and proton pump inhibitors has been able to cure gastrointestinal diseases requiring surgery until now. However, most of the cured gastrointestinal disorders require long-term maintenance therapy even after recurrence, regeneration, and complete healing, and recurrence or regeneration during maintenance therapy is frequently observed. Therefore, when only histamine H ₂ receptor antagonist and proton pump inhibitor are used for the purpose of inhibiting gastric acid secretion, the most important inhibitory effect of relapse rate cannot be expected in the treatment of gastrointestinal diseases.

In addition, the gastric mucosa protective agent is generally a short-acting, high dose, and has a disadvantage in that it should be taken for a relatively long time, but it is known that the regenerated mucosa recovers similar to normal. Therefore, in recent years, along with gastric acid inhibitors such as antacids, histamine H ₂ receptor antagonists or proton pump inhibitors, sucralfat, bismuth chelate, which protect mucosa, promote tissue repair and increase mucosal blood flow, The same gastric mucoprotectant is used at the same time.

In recent years, antibiotics have been used for the purpose of removing Helicobacter pylori bacteria.

The main symptoms of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer are abdominal pain, heartburn, bloating, indigestion, burping, nausea, vomiting and bleeding. In order to alleviate the above symptoms, there are cases of taking an antacid or eating a meal quickly, but this is only temporary, and steroidal and nonsteroidal anti-inflammatory drugs are limited in use due to side effects. In particular, nonsteroidal anti-inflammatory drugs, such as aspirin and ibuprofen, have been severely restricted in their use, such as aggravating stomach ulcers or duodenal ulcers. Therefore, there is a need for the development of drugs that can alleviate the symptoms of gastrointestinal diseases and protect the stomach with less side effects even when taken for a long time.

Therefore, researches on the treatment of gastrointestinal diseases using herbal medicines having less side effects than chemical drugs and ensuring stability have been actively conducted. Many herbal medicines, such as mugwort, mortar, turmeric, licorice and lobules, have been studied as a treatment for gastrointestinal diseases using herbal medicines.

On the other hand, Ogapi (五加皮, Acanthopanacis Cortex) is a shrub plant belonging to the family Arboraceae, divided into five leaves. There are 15 types of agapis, including Acanthopanax senticosus (RUPR. Et MAX.) HARMS, Acanthopanax sessiliflorus (RUPR. Et MAX.) SEEM., And Acanthopanax senticosus var. Subinermis KITAGAWA. It exists and has long been classified as a medicinal herb that has no toxicity and side effects in oriental medicine and has been used as a medicinal root and wood (branch), and leaves, fruits and flowers can also be used as medicinal parts. Ogapi leaves contain chiisanoside, and roots contain not only acanthoside B, D (Acanthoside B, D) but also silrgin and coumarin glycosides. Ogapi also contains water-soluble polysaccharides that enhance immunity. Ogapi is known to be spicy, bitter, and warm in nature, acting on the liver and nerves, eliminating customs, invigorating, and clarifying essence. It also protects Oro (Frail Fever) and Lacquerware (Seven Symptoms of Frail Man), which is used for poor leg use, elevates the body and improves energy. It is known to clear the mind, to increase the willpower, to prevent the body from becoming light and old, and to cure the bad blood inside the body cleanly and cleanly. It is known to cure various symptoms such as.

As mentioned above, although various pharmacological effects are known for agar, studies on gastric mucosal protection and treatment are still insignificant.

The inventors of the present invention, while exploring among herbal medicines to develop a drug for treating gastrointestinal diseases with low side effects, confirmed that the Ogapi butanol fraction protects the damage of gastric mucosal tissues caused by Helicobacter pylori and exhibits excellent antibacterial activity. Completed.

The present invention is to provide a composition for the prevention or treatment of gastrointestinal diseases, containing the Ogapi butanol fraction as an active ingredient.

1 is a view showing the extraction and separation of the Ogapi butanol fraction of the present invention.
Figure 2 is a diagram measuring the change in the stomach weight of mice after treatment of the Ogapi butanol fraction of the present invention to mice infected with Helicobacter pylori bacteria.
3 is a diagram measuring the number of colonies of Helicobacter pylori bacteria present on the mouse after treating the Ogapi butanol fraction of the present invention to mice infected with Helicobacter pylori bacteria.
Figure 4 is a diagram illustrating the change in the gastric tissue of the mouse after treatment of the Ogapi butanol fraction of the present invention to mice infected with Helicobacter pylori bacteria.
Figure 5 is a view of the growth hypolipidemic size of the Helicobacter pylori bacteria of the Ogapi butanol fraction of the present invention.

The present invention provides a composition for the prevention or treatment of gastrointestinal diseases selected from the group consisting of gastritis, gastric ulcer and duodenal ulcer caused by the bacterium Helicobacter pylori containing an ogapi butanol fraction as an active ingredient.

The composition includes a pharmaceutical composition and a food composition.

Hereinafter, the present invention will be described in detail.

Ogapi butanol fraction as an active ingredient of the composition according to the present invention is prepared by the following method. First, the extract is extracted with a mixed solvent of water and C ₁ -C ₄ alcohol (repeat three times). The extract was filtered, concentrated under reduced pressure, and lyophilized to obtain crude alcohol extract in powder form. The C ₁ ~ C ₄ alcohol may be selected from 1 to 100% methanol, 1 to 100% ethanol (alcohol), preferably 1 to 100% ethanol (alcohol), more preferably 60 to 95% ethanol ( Spirit). The crude alcoholic extract of powdered form was suspended in distilled water, extracted and separated sequentially with n-hexane, ethyl acetate, n-butanol, and then concentrated under reduced pressure and lyophilized to obtain an organobutanol fraction in powder form.

The ogapi can be used alone or in combination with leaves, wood (stems and branches), roots, berries, flowers, etc., Acanthopanax senticosus (RUPR. Et MAX.) HARMS, Acanthopanax senticosus var.subinermis KITAGAWA, Acanthopanax sessiliflorus (RUPR. Et MAX.) SEEM., Acanthopanax chiisanense NAKAI ( Acanthopanax koreanum NAKAI), Acanthopanax rufinerve Nakai, Acanthopanax seoulense Nakai), Acanthopanax sieboloians ) and acacia ( Acanthopanax sieboldianum MAKINO) preferably includes one or more selected from the group consisting of.

When the Ogapi butanol fraction of the present invention was administered to mice infected with Helicobacter pylori, concentration-dependently reduced the stomach weight of the mouse to recover to the stomach weight of normal mice, H. pylori Reduces the number of colonies present in the stomach of mice infected by 80% to 90%, and damages the gastric mucosa area and restores the thickened gastric tissue to the original state, thereby protecting the gastric mucosal tissues caused by H. pylori do. In addition, the Ogapi butanol fraction of the present invention shows excellent antimicrobial activity.

As described above, the organobutanol fraction of the present invention significantly inhibits the growth of Helicobacter pyrrole, thereby protecting the damage of gastric mucosal tissues caused by Helicobacter pylori and exhibiting excellent antibacterial activity. Therefore, the ogapi butanol fraction according to the present invention can be used as a medicine and health functional food useful for the prevention or treatment of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer.

The composition of the present invention may contain one or more known active ingredients having a prophylactic or therapeutic effect of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer together with the ogapi butanol fraction.

The composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into injectable solutions, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by a suitable method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The composition of the present invention can be administered orally or parenterally (eg, applied intravenously, subcutaneously, intraperitoneally or topically) according to the desired method, and the dosage is based on the weight, age, sex and health of the patient. The range varies depending on the diet, the time of administration, the method of administration, the rate of excretion and the severity of the disease. The daily dosage of the Ogapi butanol fraction is about 15-4,000 mg / kg, preferably divided once to several times daily.

The composition of the present invention may be used alone or in combination with methods using surgery, hormone therapy, drug treatment and biological response modifiers for the prevention or treatment of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer.

The composition of the present invention may be added to a dietary supplement for the purpose of improving gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer. When the organo butanol fraction of the present invention is used as a food additive, the organo butanol fraction may be added as it is or used with other foods or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). Generally, in the preparation of foods or beverages, the ogapi butanol fraction of the present invention is added in an amount of up to 15% by weight, preferably up to 10% by weight relative to the raw material. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and includes all of the dietary supplements in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Natural carbohydrates described above are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The proportion of the natural carbohydrate is generally about 0.01-0.20 g, preferably about 0.04-0.10 g per 100 ml of the composition of the present invention.

In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the composition of the present invention may contain a pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.01 to 0.20 parts by weight per 100 parts by weight of the composition of the present invention.

Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the present invention is not limited by the examples.

Example 1  : Preparation of Pleurotus japonica Butanol Fraction

1. Preparation of Siberian Wood Extract of Crude Alcohol

Acanthopanax senticosus (RUPR. Et MAX.) HARMS woody parts (stems and branches) were shaded and shredded. 500 g of shredded prickly wood was added to a round bottom flask, and 5.0 L of 70% ethanol (alcohol) was added thereto, followed by extraction three times at 65 to 80 ° C for 4 hours. The combined extracts were filtered and concentrated under reduced pressure to about 10 brix. The concentrate was dried with a vacuum freeze dryer to obtain 21.8 g of crude crude extract 70% ethanol (alcohol) in powder form.

2. Preparation of Woody Butane Fraction

A solution of water and n-hexane mixed at a ratio of 1: 1 (v / v) was added to the crude wood extract 70% ethanol (alcohol) crude extract in the powder form obtained in step 1, and then shaken vigorously at least 150 times and saturated twice. After standing still, the mixture was separated into a hexane layer and an aqueous layer. Ethyl acetate was mixed at a ratio of 1: 1 (v / v) in the separated aqueous layer, and the ethyl acetate layer and the aqueous layer were separated. In the separated aqueous layer, n-butanol was mixed in a 1: 1 (v / v) ratio to separate the butanol layer and the aqueous layer. Each fraction was concentrated in a rotary vacuum concentrator, lyophilized to obtain a fraction in powder form. The amount of each fraction was 0.35 g of hexane layer, 1.94 g of ethyl acetate (EtOAc) layer, 9.52 g of butanol (BuOH) layer, and 9.79 g of water (H ₂ O) layer. Of the four thorny oak woody fractions obtained above, thorny oak woody butaneol fraction (BuOH) was used as a sample for animal experiments.

Extraction and separation process of the Ogapi butanol fraction of the present invention is shown in FIG.

Experimental Example 1  : Efficacy test on Helicobacter pylori bacteria of Ogapi butanol fraction according to the present invention

In order to confirm the efficacy of Helicobacter pylori bacteria of the Ogapi butanol fraction according to the present invention, the following experiment was performed.

1. Experimental animals

Experimental animals were given SPF (specific pathogen free) BALB / c mice at 5 weeks of age from Daehan Biolink Co., Ltd. under certain conditions (temperature: 20 ± 2 ℃, relative humidity: 40 ~ 60%, contrast: 12 hours). The animals were reared for 6 days under light and dark cycles. Feed was freely consumed sterilized purina feed, a solid feed for experimental animals, and water was freely ingested after disinfecting the tap water with an ultraviolet sterilizer. 24 hours before the start of the experiment only watered and fasted. Only mice deemed to have good health were selected and used in the experiment. The experimental group was divided into eight groups, and 10 animals were allocated to each experimental group.

Since the organo butanol fraction is about 44% of the total amount of the organo fraction, the baseline of dose setting was set to 50% of the amount of crude alcohol extract in order to evaluate the efficacy relative to the organo alcohol crude extract. Table 1 shows the experimental group and the dose.

Experimental group H. pylori (KCTC 12083) Number of animals Normal Do not inoculate 10 Control group inoculation 10 Thorny skin
70% Ethanol (Alcohol) Crude Extract 50 mg / kg inoculation 10 150mg / kg 10 300 mg / kg 10 Thorny skin
Butanol fraction 25mg / kg inoculation 10 75mg / kg 10 150mg / kg 10

2. Helicobacter pylori bacteria H. pylori , KCTC 12083) and Infection

H. pylori is a Brucella agar medium containing 10% (v / v) sheep blood, 10 µg / ml vancomycin, 25 µg / ml nalidixic acid, and 5 µg / ml amphotericin B. (Brucella Broth agar (BD, France)), and then incubated in 37 ℃, 10% CO ₂ incubator. Colonies generated after incubation were tested for urease and catalase, gram staining and H. pylori. It was confirmed that. All antibiotics were from Sigma-aldrich.

In mouse using a sonde for mice 1 × 10 ⁹ CFU / ㎖ of the H. pylori were inoculated one by one to two days 0.1㎖ per interval in the same way twice (three times in total) vaccination with H. pylori bacteria for mouse Was infected.

3. General Symptoms and Death of Helicobacter Pylori Infected Mice

H. pylori Two weeks after inoculation, the samples prepared in Example 1 (barium oak skin part 70% ethanol (alcohol) crude extract, spiny oak tree part butanol fraction) were administered, and the general symptoms and death animals every hour from 1 hour to 6 hours after administration Was observed. In addition, all the surviving animals were anesthetized with ether, then opened, bleeding dead, and visually observed all internal organs.

As a result, no dead animals were observed in the eight experimental groups. Therefore, the LD ₅₀ value of the organobutanol fraction of the present invention was determined to be higher than 300 mg / kg. In addition, it was confirmed that there is no damage to the internal organs of the live animals.

4. Measurement of gastric weight changes in mice infected with Helicobacter pylori

H. pylori Two weeks after inoculation, the sample prepared in Example 1 (barium oak wood part 70% ethanol (alcohol) crude extract, spiny oak wood part butanol fraction) was supplied for two weeks, and four weeks after the inoculation, the animals were sacrificed to sacrifice the stomach. It was taken out and weighed.

The results are shown in Table 2 and FIG.

Experimental group Upper mouse weight (g) Normal 0.30 ± 0.03 Control group 0.35 ± 0.04 Thorny skin
70% Ethanol (Alcohol) Crude Extract 50 mg / kg 0.32 ± 0.05 150mg / kg 0.30 ± 0.03 300 mg / kg 0.28 ± 0.02 Thorny skin
Butanol fraction 25mg / kg 0.33 ± 0.04 75mg / kg 0.30 ± 0.03 150mg / kg 0.28 ± 0.04

As shown in Table 2 and Figure 2, in the case of the control group compared to the normal group of the stomach weight of the mouse was increased by about 17%, Ogapi butanol fraction treatment group of the present invention concentration-dependently reduced the stomach weight of the mouse normal group It was confirmed that the mouse's stomach weight was recovered.

5. Determination of colony counts of Helicobacter pylori bacteria present in mice infected with Helicobacter pylori bacteria

H. pylori The stomach of the infected mice was excised and half of the extracted stomach was homogenized at 16,000 rpm for 1 minute using a homogenizer (Tokken Inc. Japan), and then diluted to 1/10 and incubated for 5 days. After incubation, the number of colonies was counted and then converted into log values.

The results are shown in Table 3 and FIG.

Experimental group Colony count log value (CFU) Normal - 0.00 Control group 2,916,667 6.46 Thorny skin
70% Ethanol (Alcohol) Crude Extract 50 mg / kg 2,447,429 6.39 150mg / kg 2,328,500 6.37 300 mg / kg 1,610,800 6.21 Thorny skin
Butanol fraction 25mg / kg 412,750 5.62 75mg / kg 404,571 5.61 150mg / kg 398,222 5.60

Table 3 and as shown in Figure 3, gasiohgapi xylem 70% alcohol (ethanol) is treated crude extract sikyeoteuna the number of colonies present on the mice infected with H. pylori bacteria reduce 16 ~ 45%, gasiohgapi xylem butanol fraction group is H The number of colonies in the stomach of mice infected with pylori was reduced by 86%.

6. Observation of gastric tissue changes in mice infected with Helicobacter pylori: paraffin section method

H. pylori The stomach of the mice infected with the bacterium was excised and the extracted stomach tissue was placed in 10% formalin solution, shaken for one day, and stored. The stomach tissue contained in formalin was removed, unnecessary portions such as ligands were removed, cut into 0.5 cm, placed in a cassette, and washed with flowing water for at least 6 hours. The washed cassette was removed and placed in an Enclosed Tissue Processor (Sakura Finetechnical Co. Japan) to operate the machine. After the machine was finished, the cassette was removed and placed in a tissue wrapper (Leica Microsystems Inc., Germany) set at 65 ° C. After removing the stomach tissue from the cassette, discard the cassette cover, pour paraffin into the metal mold, fix the stomach tissue in the center of the mold, and place the cassette body part to harden it. After removing the metal mold from the solidified, the unnecessary paraffin portion of the cassette body portion was removed and stored at -20 ° C or less for one day. Then, the block was placed in a tissue cutter, cut into 4 μm, floated in water at 60 ° C., and the cut pieces were stretched out so that the cut pieces were placed in the center so that the pieces were removed. Prior to H & E staining, the slides to be dyed were placed in a dryer at 55-65 ° C. for at least 2 hours to ensure that the slides and paraffin pieces were tightly adhered and stained. H. pylori after H & E staining The stomach of the mice infected with the bacterium was excised and the change of the stomach tissue of the mouse was observed under a microscope (Olympus JP / BX51, 100 times) using the paraffin section method. The observation program used Image partner 3.5.231 (Image partnership co. Ltd).

The results are shown in FIG.

As shown in Figure 4, H. pylori Stomach internal tissues of mice infected with bacteria were thickened and tissue space increased, but in the Ogapi butanol fraction-administered group of the present invention, the damage of gastric mucosa area was reduced and the thickened gastric tissues returned to their original state. there was. Accordingly, it can be seen that the organobutanol fraction of the present invention protects the tissues of the gastric mucosa by H. pylori .

Experimental Example 2  : Helicobacter pylori bacterium inhibitory effect of Ogapi butanol fraction according to the present invention: Paper disk (paper disk, agar diffusion method) method

In order to confirm the inhibitory effect of Helicobacter pyrroli bacteria of the Ogapi butanol fraction according to the present invention, the following experiment was performed.

The 10 mm paper disc was sterilized at 121 ° C. for 15 minutes and dried in a 90 ° C. dryer. Samples prepared on dried paper discs (Ogapi ethyl acetate fraction, Ogapi butanol fraction, Ogapi water fraction) were absorbed and dried on a sterile work bench. At this time, the concentration of the sample was serially diluted from 280 μg per paper disc to 1/2 fold to detect antimicrobial activity. Ogapi hexane fraction was excluded from the experiment because it is difficult to control the trace amount. Harvest whole colonies of 2 plates incubated for 3 days at 37 ° C in an aerobic state (10% CO ₂ , 5% O ₂ , 100% humidity) in Brucella agar medium and suspended in 1 ml sterile water (1 x 10 ⁸ CFU) was used as a strain solution. 100 μl each of the strain solution was plated in fresh Brucella agar medium to be used for activity screening, and aseptically absorbed samples were transferred by arranging dry paper disks. Incubated for 72 hours in an aerobic state and confirmed the size of the growth zone (clear zone) formed by the growth of H. pylori was measured. Growth-lowering ring size is the average of the results obtained by repeating three or more times for each sample.

The results are shown in FIG.

As shown in FIG. 5, the antibacterial activity of the Ogapi ethyl acetate fraction and the Ogapi water fraction was insignificant, but in the Ogapi butanol fraction, the growth inhibition ring size was 22 ± 2 mm at 280 μg concentration and 18 ± 2 at 140 μg concentration. 15 ± 2 mm at the concentration of ㎜ and 70 ㎍ showed excellent antimicrobial activity.

Examples of formulations for the composition of the present invention are illustrated below.

Formulation Example 1  : Preparation of Pharmaceutical Formulations

1. Preparation of powder

2 g of Ogapi butanol fraction

1g lactose

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of tablets

Ogapi Butanol Fraction 100mg

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of Capsule

Ogapi Butanol Fraction 100mg

Corn Starch 100mg

Lactose 100mg

2 mg magnesium stearate

After mixing the above components, the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.

Formulation Example 2  : Manufacture of food

Foods comprising the Ogapi butanol fraction of the present invention were prepared as follows.

1. Preparation of Cooking Seasonings

Ogapi butanol fraction 20 to 95% by weight to prepare a cooking seasoning for health promotion.

2. Preparation of Tomato Ketchup and Sauce

Health-promoting tomato ketchup or sauce was prepared by adding 0.2-1.0% by weight of the Ogapi butanol fraction to tomato ketchup or sauce.

3. Manufacturing of Flour Foods

0.5-5.0% by weight of the Ogapi butanol fraction was added to the flour, and bread, cake, cookies, crackers and noodles were prepared using the mixture to prepare foods for health promotion.

4. Preparation of soups and gravy

0.1-5.0% by weight of the Ogapi butanol fraction was added to soups and broths to prepare meat products for health promotion, soups of noodles and broths.

5. Preparation of Ground Beef

10% by weight of the organo butanol fraction was added to the ground beef to prepare a ground beef for health promotion.

6. Manufacture of Dairy Products

5-10% by weight of the Ogapi butanol fraction was added to the milk, which was used to prepare various dairy products such as butter and ice cream.

Formulation Example 3  : Preparation of Beverages

1. Preparation of Carbonated Drinks

Ogapi butanol fractions 10-15%, sugar 5-10%, citric acid 0.05-0.3%, caramel 0.005-0.02%, vitamin C 0.1-1% of the additives, and 75-80% of purified water mixed with syrup made. The syrup was sterilized at 85 to 98 ° C. for 20 to 180 seconds, mixed with cooling water at a ratio of 1: 4, and 0.5 to 0.82% of carbon dioxide was injected to prepare a carbonated beverage containing the Ogapi butanol fraction of the present invention.

2. Manufacture of health drinks

Ogapi butanol fraction (2.5% solids, 97.16%), jujube extract (65 brix, 2.67%), complex extract (70% solids, 0.12%), vitamin C (0.02%), calcium pantonthenate (0.02%), licorice A homogeneous blend of extracts (65% solids, 0.01% solids) was instantaneously sterilized and then packaged in small packaging containers such as glass bottles and plastic bottles to prepare healthy drinks.

3. Preparation of Vegetable Juice

Five grams of Ogapi butanol fraction was added to 1,000 ml of tomato or carrot juice to prepare vegetable juice for health promotion.

4. Preparation of Fruit Juice

1 g of the Ogapi butanol fraction was added to 1,000 ml of apple or grape juice to prepare a fruit juice for health promotion.

Ogapi butanol fraction of the present invention significantly inhibits the growth of Helicobacter pylori bacteria to protect the damage of gastric mucosal tissues caused by Helicobacter pylori bacteria and exhibits excellent antibacterial activity. Therefore, the ogapi butanol fraction according to the present invention can be usefully used for the prevention or treatment of gastrointestinal diseases such as gastritis, gastric ulcer and duodenal ulcer.

Claims (5)

A composition for the prophylaxis or treatment of gastrointestinal diseases selected from the group consisting of gastritis, gastric ulcer and duodenal ulcer caused by Helicobacter pylori bacterium containing the organo butyol fraction as an active ingredient. The method for preventing or treating gastrointestinal diseases according to claim 1, wherein the organo butanol fraction is obtained by sequentially extracting and separating the organo alcohol crude extract with n-hexane, ethyl acetate and n-butanol. The method for preventing or treating gastrointestinal diseases according to claim 1, wherein the organ clove is mixed with one or more selected from the group consisting of leaves, wood parts (stems and branches), roots, fruits and flowers. The method of claim 1, wherein the agar is Acanthopanax senticosus (RUPR. Et MAX.) HARMS, Acanthopanax senticosus var. Subinermis KITAGAWA, Acanthopanax sessiliflorus (RUPR. Et MAX.) SEEM. ), Jiri Acanthopanax wood (Acanthopanax chiisanense NAKAI), island Acanthopanax wood (Acanthopanax koreanum NAKAI), hair Acanthopanax wood (Acanthopanax rufinerve NAKAI), Seoul Acanthopanax wood (Acanthopanax seoulense NAKAI), per Acanthopanax (Acanthopanax sieboloians) and Keo wood (Acanthopanax sieboldianum MAKINO) composition for the prevention or treatment of gastrointestinal diseases, characterized in that it comprises one or more selected from the group consisting of. According to claim 1, wherein the composition is a composition for the prevention or treatment of gastrointestinal diseases, characterized in that the pharmaceutical composition or food composition.

Images